14 August 2023 | Monday | News
Image Source : Public Domain
The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix® and blue light cystoscopy (BLC) versus white light cystoscopy in patients with non-muscle invasive bladder cancer (NMIBC) including tumors with stage carcinoma in situ (CIS), Ta, and T1.
A total of 158 patients were enrolled in this study. The completed statistical analysis results indicate that the study has been successfully conducted and has achieved the primary endpoint. The results of the study will be presented at upcoming academic conferences.
In January 2021, Asieris entered into a license agreement with Photocure ASA (Photocure, OSE:PHO), a bladder cancer specialty company based in Oslo, Norway, to obtain the exclusive registration and commercialization rights of Hexvix® in mainland China and Taiwan.
"The clinical data of Hexvix® further confirms its outstanding clinical performance. We sincerely thank all the researchers and participants for their dedication and efforts in advancing this clinical study." said Dr. Linda Wu, Chief Development Officer of Asieris, "This marks a significant milestone in our company's comprehensive efforts to create an integrated diagnostic and therapeutic solution in the field of bladder cancer. We will continue to vigorously advance the follow-up work, aiming to achieve commercialization and benefit more bladder cancer patients as soon as possible."